• CytoDyn and Biomm enter leronlimab supply agreement pharmaceutical-technology
    April 09, 2021
    CytoDyn (CYDY) and Biomm have signed an exclusive supply and distribution agreement that will enable the latter to market CCR5 antagonist leronlimab (PRO 140) in Brazil on receiving regulatory approval.
PharmaSources Customer Service